Hokkaido University

Toagosei Company, Ltd.

Ayato Takada

Tetsuhiko Yoshida

Nahoko Baileykobayashi

Shinya Ogawa

Wakako Furuyama

Hiroko Miyamoto

Junki Maruyama

Reiko Yoshida

Shigeru Iida

The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.

Antiviral peptide and use thereof

An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.

An antiviral peptide provided by the present invention includes:

Antiviral peptide and use therefor

There has been a need for a neutralizing monoclonal antibody which is useful for antibody therapy effective against ebolavirus. The present invention provides a monoclonal antibody or an antigen-binding fragment thereof, which recognizes an internal fusion loop of ebolavirus GP and is capable of neutralizing the biological activity of ebolavirus.

Growing community of inventors

Hokkaido, Japan

Ayato Takada